Special Issue

Visualizing 3D Embryo and Tissue Morphology—a Decade of Using High-Resolution Episcopic Microscopy (HREM) in Biomedical Imaging

Message from the Guest Editors

HREM is a digital volume data generation technique, which offers near histological detail in virtual 3D data of whole embryos of biomedical model organisms and small tissue samples. Introduced over 10 years ago, the HREM user community is steadily growing and employs the method for phenotyping genetically engineered mouse embryos, biomedically challenged chick embryos and embryos of several other model organisms, as well as normal and pathological tissue samples of adult biomedical models and humans. Quite recently HREM also found its way into multimodal imaging pipelines providing holistic visualization of normal and pathologic morphology and physiology of organisms at all levels of resolution.

Guest Editors

Prof. Dr. Wolfgang J. Weninger
Division of Anatomy, Medical University of Vienna, Vienna, Austria

Dr. Stefan H. Geyer
Division of Anatomy, Medical University of Vienna, Vienna, Austria

Deadline for manuscript submissions

closed (31 October 2021)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/69397

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).